| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Stjepanovic MI et al. | Pulmonary and Vertebral Mycobacterium avium Disease in a HIV-negative 71-year-old Man - A Case Report. | 2016 | Infez Med | pmid:28011973 |
| Muñoz-Egea MC et al. | Effect of Antibiotics and Antibiofilm Agents in the Ultrastructure and Development of Biofilms Developed by Nonpigmented Rapidly Growing Mycobacteria. | 2016 | Microb. Drug Resist. | pmid:26208145 |
| Salimi A et al. | Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. | 2016 | Xenobiotica | pmid:26068526 |
| Zycinska K et al. | Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. | 2016 | Adv. Exp. Med. Biol. | pmid:27620311 |
| Bax HI et al. | Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. | 2016 | Antimicrob. Agents Chemother. | pmid:26883697 |
| Hirata Y et al. | Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. | 2016 | Int. J. Infect. Dis. | pmid:27590563 |
| Liou JM et al. | Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. | 2016 | Lancet | pmid:27769562 |
| Campillo A et al. | [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. | 2016 | Gastroenterol Hepatol | pmid:27084668 |
| Chauffour A et al. | Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. | 2016 | PLoS Negl Trop Dis | pmid:27755552 |
| Abuhammour A et al. | Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. | 2016 | Arab J Gastroenterol | pmid:27665525 |
| Matsumoto H et al. | Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. | 2016 | Dig. Dis. Sci. | pmid:27659671 |
| Rossi A et al. | Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. | 2016 | Drug Dev Ind Pharm | pmid:26065531 |
| Shichijo S et al. | Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. | 2016 | J Dig Dis | pmid:27534444 |
| Morimoto K et al. | Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. | 2016 | Ann Am Thorac Soc | pmid:27513168 |
| Christianson S et al. | Time-to-Detection of Inducible Macrolide Resistance in Mycobacterium abscessus Subspecies and Its Association with the Erm(41) Sequevar. | 2016 | PLoS ONE | pmid:27490181 |
| Harada T et al. | Premedication with Clarithromycin Is Effective against Secondary Bacterial Pneumonia during Influenza Virus Infection in a Pulmonary Emphysema Mouse Model. | 2016 | J. Pharmacol. Exp. Ther. | pmid:27489022 |
| Bonfigli AR et al. | Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. | 2016 | Nutr Metab Cardiovasc Dis | pmid:27480449 |
| Lotfipour F et al. | Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori. | 2016 | Drug Res (Stuttg) | pmid:25919643 |
| Okano Y et al. | Miliary pulmonary nodules due to Mycobacterium xenopi in a steroid-induced immunocompromised patient successfully treated with chemotherapy: a case report. | 2016 | BMC Pulm Med | pmid:27287608 |
| Steurer J | [Months of antibiotic therapy in persistent symptoms of Lyme disease without effect]. | 2016 | Praxis (Bern 1994) | pmid:27269781 |
| Chung JW et al. | Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. | 2016 | Dig Liver Dis | pmid:27257049 |
| Mitchell H and Katelaris P | Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. | 2016 | Med. J. Aust. | pmid:27256648 |
| Ullah S et al. | Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. | 2016 | Drug Deliv | pmid:27247018 |
| Parize P et al. | Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. | 2016 | J Eur Acad Dermatol Venereol | pmid:25677464 |
| Akram FE et al. | A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). | 2016 | Ann. Clin. Microbiol. Antimicrob. | pmid:27530257 |
| Bilgilier C et al. | Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. | 2016 | Ann. Hematol. | pmid:27091350 |
| Root AA et al. | Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. | 2016 | Br J Clin Pharmacol | pmid:27090996 |
| Kazama I et al. | Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells. | 2016 | Chemotherapy | pmid:27088971 |
| Huynh VA et al. | [Fixed drug eruption to clarithromycin: The importance of challenge tests in diagnosis]. | 2016 | Ann Dermatol Venereol | pmid:27080820 |
| EmiralioÄŸlu N et al. | Pulmonary Mycobacterium abscessus Infection in a Patient with Triple A Syndrome. | 2016 | J. Trop. Pediatr. | pmid:27080471 |
| Graham DY and Dore MP | Helicobacter pylori therapy: a paradigm shift. | 2016 | Expert Rev Anti Infect Ther | pmid:27077447 |
| Song ZQ et al. | Hybrid Therapy Regimen for Helicobacter Pylori Eradication. | 2016 | Chin. Med. J. | pmid:27064046 |
| Matsumoto H et al. | Molecular Detection of H. pylori Using Adherent Gastric Mucous to Biopsy Forceps. | 2016 | Helicobacter | pmid:27061611 |
| Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
| Friedman ND et al. | Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. | 2016 | Antimicrob. Agents Chemother. | pmid:26883709 |
| Chua CS et al. | The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. | 2016 | Int J Food Sci Nutr | pmid:26883189 |
| Meng X et al. | [Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province]. | 2016 | Zhonghua Yi Xue Za Zhi | pmid:26879786 |
| Bakshi SS | Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. | 2016 | J Laryngol Otol | pmid:26878377 |
| Franceschi F et al. | High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. | 2016 | Eur Rev Med Pharmacol Sci | pmid:26875899 |
| Tepeš B et al. | Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. | 2016 | Eur J Gastroenterol Hepatol | pmid:26862930 |
| Lim SG et al. | The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. | 2016 | Dig Liver Dis | pmid:26856963 |
| Çağan-Appak Y et al. | Clarithromycin resistance and 23S rRNA gene point mutations of Helicobacter pylori infection in children. | 2016 | Turk. J. Pediatr. | pmid:28276208 |
| Thung I et al. | Review article: the global emergence of Helicobacter pylori antibiotic resistance. | 2016 | Aliment. Pharmacol. Ther. | pmid:26694080 |
| Vermeer LM et al. | Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. | 2016 | Drug Metab. Dispos. | pmid:26668209 |
| Meng Y et al. | Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. | 2016 | Pharm. Res. | pmid:26666773 |
| Kamiya K et al. | Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. | 2016 | J. Dermatol. | pmid:26508502 |
| Mark TM and Coleman M | It's Time to Take Clarithromycin Seriously in Multiple Myeloma. | 2016 | Acta Haematol. | pmid:26505907 |
| Qiu XH et al. | Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. | 2016 | Acta Haematol. | pmid:26505646 |
| Lee J et al. | A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. | 2016 | J. Matern. Fetal. Neonatal. Med. | pmid:26373262 |
| Tsujimae M et al. | A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. | 2016 | Digestion | pmid:28030862 |